Mark DeMario, MD
BioNTech US Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mark DeMario, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:56 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT03597282 · A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced MelanomaBioNTech US Inc. · terminated · Metastatic Melanoma · study director
- Ph1NCT03380871 · A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung CancerBioNTech US Inc. · completed · Carcinoma, Non-Small-Cell Lung, Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung · study director
- Ph1NCT02897765 · A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder CancerBioNTech US Inc. · completed · Urinary Bladder Cancer, Bladder Tumors, Transitional Cell Carcinoma of the Bladder · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:56 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.